## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($226.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Capital Fund Management S.A. Grows Holdings in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251201T041039 | Bullish | Relevance: 98%
-  Capital Fund Management S.A. increased its stake in Universal Health Services (NYSE:UHS) by 12.9% in Q2, acquiring an additional 10,754 shares to own a total of 94,086 shares valued at $17.04 million. This comes as UHS reported strong Q3 earnings, surpassing analyst expectations with an EPS of $5.69 and revenue of $4.50 billion. Despite recent analyst upgrades, the consensus rating for UHS remains a "Hold" with an average target price of $232.64.

**2. Charles Schwab Investment Management Inc. Has $103.28 Million Position in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251130T200806 | Somewhat-Bullish | Relevance: 98%
- Charles Schwab Investment Management Inc. reduced its stake in Universal Health Services (NYSE:UHS) by 0.8% in the second quarter, now holding 570,117 shares valued at $103.28 million. Universal Health Services reported strong Q3 earnings, beating analyst expectations with EPS of $5.69 and revenue of $4.50 billion, and announced a quarterly dividend of $0.20 per share. Despite some insider selling, institutional investors own 86.05% of the company, and analysts maintain a consensus "Hold" rating with a target price of $232.64.

**3. Quadrature Capital Ltd Sells 12,151 Shares of Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251130T220854 | Somewhat-Bullish | Relevance: 97%
-  Quadrature Capital Ltd reduced its stake in Universal Health Services (NYSE:UHS) by 35.1% in the second quarter, selling 12,151 shares and retaining 22,486 shares valued at $4.07 million. This comes amidst other institutional investors adjusting their positions and recent insider selling activity by directors Warren J. Nimetz and Elliot J. Sussman. Universal Health Services reported strong quarterly earnings, beating revenue and EPS estimates, and announced a quarterly dividend.

**4. Tenet Healthcare Soars 72% YTD: But is the Rally Out of Breath?**
- Source: TradingView | 20251201T182148 | Somewhat-Bullish | Relevance: 72%
- Tenet Healthcare (THC) has seen an impressive 71.8% year-to-date gain, outperforming both its peers and the S&P 500, driven by strong demand for hospital services and strategic expansion in ambulatory care. The company's updated 2025 guidance and favorable analyst estimates reflect continued confidence, despite a somewhat stretched valuation and potential policy-related reimbursement risks. While there's still upside, its current Zacks Rank #3 (Hold) suggests a more balanced outlook compared to earlier in the year.

**5. Tenet Healthcare Soars 72% YTD: But is the Rally Out of Breath?**
- Source: Finviz | 20251201T162300 | Neutral | Relevance: 68%
- Tenet Healthcare has seen a significant 71.8% year-to-date gain, outperforming peers and the S&P 500, driven by strong demand for hospital services, expansion in ambulatory care, and positive financial guidance. Despite its strong performance, the article highlights potential risks due to a stretched valuation and policy-related reimbursement concerns, leading to a Zacks Rank #3 (Hold).

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |
| 2025-11-13 | Wells Fargo | $259 | $249 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |
| 2025-11-13 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Heavy insider selling: $31M sold (3 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +6%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 10.2 |
| Current P/E | 11.1 |
| YoY Growth | 8.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.2% to -0.2% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.73), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.19% (CS: 59) | Neutral |
| RSI_14 | 65.6 | Neutral |
| MACD Histogram | 0.73 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.110x | Above |
| vs SMA200 | 1.272x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $239.43
- **Stop Loss:** $226.87 (5.2% risk)
- **Target:** $251.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $14,126.37
- **Portfolio %:** 14.13%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*